Back to News
Market Impact: 0.3
Viridian Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and $24.7 Million in Lumvoa Net Product Revenue
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Viridian Therapeutics reported $24.7 million in Lumvoa net product revenue for the third quarter ended September 30, 2026, with more than 100 patients on therapy at quarter-end. The provided article text ends before additional financial results are disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
VRDN0.45
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings
- Snap shares fall over 10% on third-quarter earnings miss